Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Qualigen Therapeutics, Inc. (QLGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5645-0.0175 (-3.01%)
At close: 04:00PM EDT
0.5650 +0.00 (+0.09%)
After hours: 07:57PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.5820
Open0.5800
Bid0.5801 x 1300
Ask0.5885 x 3000
Day's Range0.5645 - 0.6100
52 Week Range0.4500 - 3.1200
Volume182,235
Avg. Volume1,180,683
Market Cap21.9M
Beta (5Y Monthly)0.26
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for QLGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Qualigen Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 01/04/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    6 months agoArgus Research
View more
  • GlobeNewswire

    Qualigen Therapeutics to Present at BIO International Convention

    Qualigen Therapeutics, Inc. Tariq Arshad CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics will present a corporate overview at the BIO International Convention to be held on June 13 – 16, 2022 at the San Diego Convention Cent

  • GlobeNewswire

    Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials

    A Potential Treatment for Pancreatic Cancer in Addition to Other Tumors of High Unmet Clinical Need CARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has initiated Investigational New Drug, or IND-enabling, studies for its lead therapeutic program, Q

  • Zacks Small Cap Research

    QLGN: Acquires Majority Stake in Israeli Diagnostics Technology Company NanoSynex…

    By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update Acquires Majority Stake in NanoSynex On May 3, 2022, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) entered into a definitive agreement to acquire a majority stake in NanoSynex Ltd., an Israeli-based diagnostics company developing the Antimicrobial Susceptibility Testing (AST) platform. The goal of AST is to provide

Advertisement
Advertisement